Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
JASPER: Niraparib +/- PD-1 Inhibitor in NSCLC
NCT03308942Phase 2Completed
- Start
- Sep 2017
- Primary completion
- May 2020
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of niraparib in non-small cell lung cancer (NSCLC). Started Sep 2017; status: completed.
02
Drugs
niraparib
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT03308942.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03308942.